Ultragenyx Pharmaceutical has been granted a patent for a method to protect AAV viral particles during heat inactivation. The method involves heating a sample containing AAV particles and helper virus particles to a temperature of 45-55°C in the presence of specific buffers. GlobalData’s report on Ultragenyx Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ultragenyx Pharmaceutical, Adeno-associated virus vectors was a key innovation area identified from patents. Ultragenyx Pharmaceutical's grant share as of May 2024 was 25%. Grant share is based on the ratio of number of grants to total number of patents.
Method of protecting aav viral particles during heat inactivation
A recently granted patent (Publication Number: US11944658B2) discloses a method for inactivating helper virus in a sample containing adeno-associated virus particles. The method involves heating the sample to a specific temperature range of 45°C to 55°C and maintaining it for a duration of 10 to 180 minutes. This process results in a significant log reduction of the helper virus, specifically 6.3 or greater, ensuring effective inactivation.
Furthermore, the method utilizes a buffer containing divalent or trivalent cations within a concentration range of 25 mM to 500 mM, or kosmotropic salts within a concentration range of 0.5 M to 0.6 M. The buffer composition also includes additional components such as chaotropic salts and polyols like glycerol, propylene glycol, or 1,6-Hexanediol. The pH of the buffer is maintained between 3.0 to 10.0 at varying temperatures. Additionally, specific cations like Mg2+, Ca2+, Mn2+, Ni2+, Zn2+, Co2+, Sr2+, Cu2+, Cr2+, and Sc3+ are used in the buffer to facilitate the inactivation process. The method offers versatility in buffer selection, including Tris, phosphate, or triazolamine buffers, and allows for the inactivation of helper viruses like adenovirus, particularly Ad5, making it a promising approach in virology research and biotechnology applications.
To know more about GlobalData’s detailed insights on Ultragenyx Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
